Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TTRX
STRONG SELLTurn Therapeutics Inc. · Healthcare · United States · $254M · Avg Vol: $808K/d
10
StockRankGet insider-trade alerts
Q
16
V
22
M
48
P/E (TTM)
—
ROE
-129.2%
D/E
1.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+28.7%
SMA 50SMA 200
Close
$7.78
RSI (14)
33.6
52W High
$26.50
From 52W High
0.3%
SCORE BREAKDOWN
Quality
16
ROIC (ROA)
—N/A
ROE
-129.2%7.0
GP/Assets
-47.6%1.4
Op. Margin
0.0%41.3
FCF/Assets
-71.3%3.1
Piotroski
111.4
Int. Cover
—N/A
D/E Ratio
0.98x14.8
Current Ratio
2.23x42.5
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-32.6x25.0
P/FCF
—N/A
P/B
41.7x2.2
P/S
—N/A
Div Yield
—N/A
Momentum
48
52W High %
29%7.4
RS 6M
52%94.0
SMA 50/200
1.47x97.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-15%15.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$254M
P/E (Forward)
-56.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TTRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TTRX | Turn Therapeutics Inc.(you) | $254M | 10 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
| NMRA | Neumora Therapeutics, Inc. | $276M | 10 | STRONG SELL |
| OTLK | Outlook Therapeutics, Inc. | $263M | 11 | STRONG SELL |
| GALT | Galectin Therapeutics Inc. | $229M | 9 | STRONG SELL |
| TRDA | Entrada Therapeutics, Inc. | $227M | 8 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $222M | 9 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| IRD | Opus Genetics, Inc. | $254M | 14 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%